TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials

Benzinga Logo Benzinga By Vandana Singh
Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials

Arrowhead Pharmaceuticals reported positive interim Phase 1/2a trial results for its obesity drugs ARO-INHBE and ARO-ALK7, which use RNA interference to target fat storage pathways. ARO-INHBE doubled weight loss and tripled fat reductions when combined with Eli Lilly's tirzepatide, while ARO-ALK7 showed rapid visceral fat reductions. Both candidates were well-tolerated, and the stock surged 17.81% to a new 52-week high.

Insights
HLBAY   positive

Actively pursuing acquisition of Avadel with a competitive proposal that values the company at approximately $2.4 billion


ARWR   positive

Company announced significant positive interim trial results showing meaningful fat loss and weight reduction with its obesity drug candidates. Both drugs demonstrated dose-dependent efficacy and good tolerability. Stock price surged 17.81% to a new 52-week high, reflecting strong market confidence in the clinical progress.